<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title>BMC Cancer</journal-title><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2407-9-172</article-id><article-id pub-id-type="pmid">19500394</article-id><article-id pub-id-type="doi">10.1186/1471-2407-9-172</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Genetic variants in FGFR2 and FGFR4 genes and skin cancer risk in the Nurses' Health Study</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Nan</surname><given-names>Hongmei</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>hnan@hsph.harvard.edu</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Qureshi</surname><given-names>Abrar A</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>aqureshi@partners.org</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Hunter</surname><given-names>David J</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>David.Hunter@channing.harvard.edu</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Han</surname><given-names>Jiali</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>jiali.han@channing.harvard.edu</email></contrib></contrib-group><aff id="I1"><label>1</label>Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA</aff><aff id="I2"><label>2</label>Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA</aff><aff id="I3"><label>3</label>Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>6</day><month>6</month><year>2009</year></pub-date><volume>9</volume><fpage>172</fpage><lpage>172</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/9/172"/><history><date date-type="received"><day>5</day><month>12</month><year>2008</year></date><date date-type="accepted"><day>6</day><month>6</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Nan et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Nan et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Nan Hongmei hnan@hsph.harvard.edu </dc:author><dc:title> Genetic variants in FGFR2 and FGFR4 genes and skin cancer risk in the Nurses' Health Study </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>BMC Cancer 9(1): 172-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2407(2009)9:1&#x0003c;172&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2407</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>The human fibroblast growth factor (FGF) and its receptor (FGFR) play an important role in tumorigenesis. Deregulation of the <italic>FGFR2 </italic>gene has been identified in a number of cancer sites. Overexpression of the <italic>FGFR4 </italic>protein has been linked to cutaneous melanoma progression. Previous studies reported associations between genetic variants in the <italic>FGFR2 </italic>and <italic>FGFR4 </italic>genes and development of various cancers.</p></sec><sec sec-type="methods"><title>Methods</title><p>We evaluated the associations of four genetic variants in the <italic>FGFR2 </italic>gene highly related to breast cancer risk and the three common tag-SNPs in the <italic>FGFR4 </italic>gene with skin cancer risk in a nested case-control study of Caucasians within the Nurses' Health Study (NHS) among 218 melanoma cases, 285 squamous cell carcinoma (SCC) cases, 300 basal cell carcinoma (BCC) cases, and 870 controls.</p></sec><sec><title>Results</title><p>We found no evidence for associations between these seven genetic variants and the risks of melanoma and nonmelanocytic skin cancer.</p></sec><sec><title>Conclusion</title><p>Given the power of this study, we did not detect any contribution of genetic variants in the <italic>FGFR2 </italic>or <italic>FGFR4 </italic>genes to inherited predisposition to skin cancer among Caucasian women.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>The human fibroblast growth factor (FGF) and its receptor families consist of 22 structurally related FGF members and four high-affinity tyrosine kinase FGF receptors (FGFR1 to 4) [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. The four FGFRs generate ligand-binding specific isoforms by tissue-specific alternative mRNA splicing of the genes [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B7">7</xref>]. FGFs and their receptors have an important role in cell signaling [<xref ref-type="bibr" rid="B8">8</xref>]. The formation of the FGF-FGFR complex activates the intracellular tyrosine kinase, which mediates signal transduction through the direct phosphorylation of adaptor proteins [<xref ref-type="bibr" rid="B9">9</xref>]. These complex FGF signaling networks are crucial in the multiple cell biological activities, such as proliferation, differentiation, mitogenesis, migration, and apoptosis, and are thus implicated in tumorigenesis [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B12">12</xref>].</p><p>The <italic>FGFR2</italic>, known as a unique high-affinity receptor for keratinocyte growth factor (KGF or FGF7), is expressed in the keratinocytes of the skin epidermis, hair follicles, and mesenchymal tissues [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>]. An experiment in transgenic mice with <italic>FGFR2 </italic>mutation in the keratinocyte showed that normal signal transduction was blocked by binding of its ligand KGF [<xref ref-type="bibr" rid="B15">15</xref>]. It has been reported that the <italic>FGFR2 </italic>plays a role in tumor suppression in the skin [<xref ref-type="bibr" rid="B16">16</xref>]. In addition, the increased <italic>FGFR2 </italic>gene expression has been related to the genetic variants in intron 2 of the <italic>FGFR2 </italic>gene [<xref ref-type="bibr" rid="B17">17</xref>] and deregulation of <italic>FGFR2 </italic>gene expression and/or gene mutation has been identified in various kinds of human cancers, such as breast, prostate, endometrial, colon, bladder, and thyroid cancers [<xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B22">22</xref>]. Recently, two genome-wide association studies have identified some genetic variants in the <italic>FGFR2 </italic>gene that were highly associated with breast cancer [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>].</p><p>The <italic>FGFR4 </italic>gene located on the chromosome 5 spans approximately 11.3 kb and is composed of 18 exons [<xref ref-type="bibr" rid="B25">25</xref>]. Overexpression of the FGFR4 protein has been associated with cutaneous melanoma progression [<xref ref-type="bibr" rid="B26">26</xref>]. High expression of FGFR4 has also been observed in breast cancer, prostate cancer, pancreatic cancer, and renal cell carcinoma [<xref ref-type="bibr" rid="B27">27</xref>-<xref ref-type="bibr" rid="B30">30</xref>]. Furthermore, SNP rs351855 located in exon 9 of the <italic>FGFR4 </italic>gene results in an amino acid change (Gly388Arg) in the transmembrane domain of the receptor and has been associated with tumor progression in, for example, cutaneous nodular malignant melanoma, breast cancer, lung adenocarcinoma, prostate cancer, and head and neck cancer [<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B31">31</xref>-<xref ref-type="bibr" rid="B36">36</xref>].</p><p>We conducted a nested case-control study of Caucasians within the Nurses' Health Study (NHS) to evaluate whether the four breast cancer-related SNPs in the <italic>FGFR2 </italic>gene (rs11200014, rs2981579, rs1219648, and rs2420946) [<xref ref-type="bibr" rid="B24">24</xref>] and the three common variants (tag-SNPs) in the <italic>FGFR4 </italic>gene (rs1966265, rs376618, and rs351855) are associated with the risk of three skin cancer types including melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC).</p></sec><sec sec-type="methods"><title>Methods</title><p>Eligible cases in this study consisted of women with incident skin cancer from the subcohort of the NHS who gave a blood specimen in 1989&#x02013;1990 (<italic>n </italic>= 32,826), including SCC and BCC cases with a diagnosis any time after blood collection up to June 1, 1998 and melanoma cases up to June 1, 2000 with no previously diagnosed skin cancer. A common control series was randomly selected from participants who gave a blood sample and were free of diagnosed skin cancer up to and including the questionnaire cycle during which the case was diagnosed. One or two controls were matched to each case by year of birth (&#x000b1; 1 year). All subjects were drawn from the U.S. non-Hispanic Caucasian women in this study. The nested case-control study consisted of 218 incident melanoma cases, 285 incident SCC cases, a sample of 300 BCC cases from the large number of incident cases, and 870 age-matched controls. The informed consent was obtained from the participants in this study. The study protocol was approved by the Committee on Use of Human Subjects of the Brigham and Women's Hospital, Boston, MA.</p><p>We obtained information regarding skin cancer risk factors from the prospective biennial questionnaires and a retrospective supplementary questionnaire. Information on natural hair color at age 20 and childhood and adolescent tanning tendency were collected in the 1982 prospective questionnaire. Ethnic group was ascertained in the 1992 questionnaire. In the skin cancer nested case-control study, natural skin color and other sun exposure-related information were collected by the retrospective supplementary questionnaire in 2002. The response rates of cases and controls were 92% and 89%, respectively. A cumulative lifetime sun exposure while wearing a bathing suit for each individual was developed by combining the UV database and the information obtained from the supplementary questionnaires. We constructed a multivariate confounder score to create a constitutional susceptibility score [<xref ref-type="bibr" rid="B37">37</xref>], summarizing natural skin color, natural hair color, child or adolescent tendency to burn, and the number of palpably raised moles on arms. We used this score to define women with constitutional susceptibility [<xref ref-type="bibr" rid="B38">38</xref>]. In addition, the 11 states of residence of cohort members at baseline were grouped into three regions: Northeast (Connecticut, Massachusetts, Maryland, New Jersey, New York, and Pennsylvania), Northcentral (Michigan and Ohio), and West and South (California, Texas, and Florida).</p><p>Information on the seven SNPs in the <italic>FGFR2 </italic>and <italic>FGFR4 </italic>genes is presented in Table <xref ref-type="table" rid="T1">1</xref>. Four SNPs in intron 2 of the <italic>FGFR2 </italic>gene (rs11200014, rs2981579, rs1219648, and rs2420946) genotyped in this study were breast cancer-related SNPs identified by a recent genome-wide association study conducted by our group [<xref ref-type="bibr" rid="B24">24</xref>]. For the <italic>FGFR4 </italic>gene, based on the HapMap phase II SNP genotype data, we chose three tag-SNPs (rs1966265, rs376618, and rs351855) as surrogates for untyped polymorphisms in the <italic>FGFR4 </italic>gene using the HapMap Project 90 (30 trios) Caucasian samples from a US Utah population with Northern and Western European ancestry collected in 1980 by the Centre d'Etude du Polymorphisme Humain (CEPH) [<xref ref-type="bibr" rid="B39">39</xref>]. Briefly, the tag-SNPs (minor allele frequency &#x0003e; 0.05) were selected using the Tagger program of (r<sup>2</sup>&#x0003e;0.8), which combines the simplicity of pairwise r<sup>2 </sup>methods [<xref ref-type="bibr" rid="B40">40</xref>] with the potential efficiency of multimarker haplotype approaches [<xref ref-type="bibr" rid="B41">41</xref>].</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Seven SNPs in the <italic>FGFR2 </italic>and <italic>FGFR4 </italic>genes</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>SNP</bold></td><td align="center"><bold>rs#</bold></td><td align="center"><bold>Chromosome</bold></td><td align="center"><bold>Location</bold></td><td align="center"><bold>MAF-controls (%)<sup>a</sup></bold></td><td align="center"><bold>MAF-CEU (%)<sup>b</sup></bold></td></tr></thead><tbody><tr><td align="center"><italic>FGFR2 </italic>intron 2</td><td align="left">rs11200014</td><td align="center">10</td><td align="center">123324920</td><td align="center">42</td><td align="center">47</td></tr><tr><td align="center"><italic>FGFR2 </italic>intron 2</td><td align="left">rs2981579</td><td align="center">10</td><td align="center">123327325</td><td align="center">42</td><td align="center">47</td></tr><tr><td align="center"><italic>FGFR2 </italic>intron 2</td><td align="left">rs1219648</td><td align="center">10</td><td align="center">123336180</td><td align="center">40</td><td align="center">47</td></tr><tr><td align="center"><italic>FGFR2 </italic>intron 2</td><td align="left">rs2420946</td><td align="center">10</td><td align="center">123341314</td><td align="center">40</td><td align="center">47</td></tr><tr><td align="center"><italic>FGFR4 </italic>Val10Ile</td><td align="left">rs1966265*</td><td align="center">5</td><td align="center">176449237</td><td align="center">-</td><td align="center">20</td></tr><tr><td></td><td align="left">rs12519145*</td><td align="center">5</td><td align="center">176488129</td><td align="center">22</td><td align="center">19</td></tr><tr><td align="center"><italic>FGFR4 </italic>Leu136Pro</td><td align="left">rs376618</td><td align="center">5</td><td align="center">176450403</td><td align="center">24</td><td align="center">26</td></tr><tr><td align="center"><italic>FGFR4 </italic>Gly388Arg</td><td align="left">rs351855</td><td align="center">5</td><td align="center">176452849</td><td align="center">31</td><td align="center">28</td></tr></tbody></table><table-wrap-foot><p>*The SNP rs1966265 failed the assay and the rs12519145 was genotyped instead (r<sup>2 </sup>= 0.8).</p><p><sup>a </sup>Minor allele frequency (MAF) was calculated among controls in this study.</p><p><sup>b </sup>MAF was based on the HapMap CEU (Utah residents with ancestry from northern and western Europe) samples.</p></table-wrap-foot></table-wrap><p>We genotyped these seven SNPs by the 5' nuclease assay (TaqMan<sup>&#x000ae;</sup>) in 384-well format, using the ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA). TaqMan<sup>&#x000ae; </sup>primers and probes were designed with the Primer Express<sup>&#x000ae; </sup>Oligo Design software v2.0 (ABI PRISM). Due to assay failure, we genotyped rs12519145 as a surrogate for the <italic>FGFR4 </italic>rs1966265 (r<sup>2 </sup>= 0.8). Laboratory personnel were blinded to case-control status, and 10% blinded quality control samples (duplicate samples) were inserted to validate genotyping procedures; concordance for the blinded quality control samples was 100%. Primers, probes, and conditions for genotyping assays are available upon request.</p><p>We used the &#x003c7;<sup>2 </sup>test to assess whether the genotypes for all seven SNPs were in Hardy-Weinberg equilibrium among the controls. We compared each type of skin cancer with the common control series to increase the statistical power. We evaluated the association between each genotype and skin cancer risk using unconditional logistic regression. An additive model was used to calculate the <italic>p</italic>-value on skin cancer risk according to an ordinal coding for genotype (0, 1 or 2 copies of SNP minor allele). For the four <italic>FGFR2 </italic>SNPs and three <italic>FGFR4 </italic>SNPs, haplotype frequencies and expected haplotype counts for each individual were estimated using a simple expectation-maximization algorithm, as implemented in SAS PROC HAPLOTYPE. The analyses of the associations between haplotypes and skin cancer risk were performed using the expectation-substitution technique [<xref ref-type="bibr" rid="B42">42</xref>]. All statistical analyses were two-sided and carried out using SAS V9.1 (SAS Institute, Cary, NC).</p><p>The Quanto statistical software version 1.2.3 was used for power calculation [<xref ref-type="bibr" rid="B43">43</xref>]. We calculated the power to detect the specified ORs at various allele frequencies of variant allele in additive models. The calculations were based on a two-sided alpha of 0.05. For melanoma (SCC or BCC), we have 80% power to detect an OR of 1.80 (1.72 or 1.70), 1.48 (1.42 or 1.41), and 1.35 (1.32 or 1.31) if the minor allele frequency is 5%, 15%, and 40%, respectively.</p></sec><sec><title>Results and discussion</title><p>A detailed description of the characteristics of cases and controls in the skin cancer nested case-control study has been provided previously [<xref ref-type="bibr" rid="B44">44</xref>]. In brief, at the beginning of the follow-up of this nested case-control study, the nurses were between 43 and 68 years old (mean age, 58.7 years). The mean ages at diagnosis for incident melanoma, SCC, and BCC cases were 63.4, 64.7, and 64.0 years, respectively. A family history of skin cancer was a risk factor for all three types of skin cancer. Skin cancer cases had lighter pigmentation (skin color and hair color), more moles on the arms, higher cumulative sun exposure while wearing a bathing suit, and more lifetime severe sunburns that blistered than controls.</p><p>The genotype distributions of the seven SNPs evaluated in this study were in Hardy-Weinberg equilibrium among controls. The minor allele frequencies of these seven SNPs among controls in this study were similar to those from HapMap CEU data. We evaluated the main effect of each polymorphism across three types of skin cancer (Table <xref ref-type="table" rid="T2">2</xref>) and observed no significant associations between these seven SNPs and skin cancer risk. The multivariate analyses controlling for age and skin cancer risk factors showed results similar to the age-adjusted analyses (Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). Furthermore, we performed a global test to evaluate the difference in <italic>FGFR2 </italic>and <italic>FGFR4 </italic>haplotype frequencies between cases and controls (Table <xref ref-type="table" rid="T3">3</xref>) and found no significant associations with skin cancer risk, which was consistent with the results of the single SNP analyses presented in Table <xref ref-type="table" rid="T2">2</xref>.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Associations between the seven SNPs in the <italic>FGFR2 </italic>and <italic>FGFR4 </italic>genes and skin cancer risk</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>SNP</bold></td><td align="center" colspan="2"><bold>Melanoma</bold></td><td align="center" colspan="2"><bold>SCC</bold></td><td align="center" colspan="2"><bold>BCC</bold></td></tr><tr><td></td><td colspan="6"><hr></hr></td></tr><tr><td></td><td align="center">Additive OR*</td><td align="center"><italic>p </italic>for trend</td><td align="left">Additive OR*</td><td align="center"><italic>p </italic>for trend</td><td align="center">Additive OR*</td><td align="center"><italic>p </italic>for trend</td></tr></thead><tbody><tr><td align="left"><italic>FGFR2 </italic>rs11200014</td><td align="center">0.95 (0.77&#x02013;1.19)</td><td align="center">0.67</td><td align="left">0.90 (0.74&#x02013;1.10)</td><td align="center">0.30</td><td align="center">1.03 (0.85&#x02013;1.26)</td><td align="center">0.73</td></tr><tr><td align="left"><italic>FGFR2 </italic>rs2981579</td><td align="center">0.96 (0.77&#x02013;1.19)</td><td align="center">0.70</td><td align="left">0.92 (0.75&#x02013;1.12)</td><td align="center">0.40</td><td align="center">1.11 (0.91&#x02013;1.36)</td><td align="center">0.29</td></tr><tr><td align="left"><italic>FGFR2 </italic>rs1219648</td><td align="center">0.96 (0.77&#x02013;1.20)</td><td align="center">0.75</td><td align="left">0.87 (0.71&#x02013;1.07)</td><td align="center">0.18</td><td align="center">1.06 (0.87&#x02013;1.29)</td><td align="center">0.57</td></tr><tr><td align="left"><italic>FGFR2 </italic>rs2420946</td><td align="center">1.08 (0.85&#x02013;1.38)</td><td align="center">0.53</td><td align="left">0.89 (0.72&#x02013;1.10)</td><td align="center">0.28</td><td align="center">0.99 (0.81&#x02013;1.21)</td><td align="center">0.91</td></tr><tr><td align="left"><italic>FGFR4 </italic>rs1966265**</td><td align="center">1.16 (0.90&#x02013;1.48)</td><td align="center">0.26</td><td align="left">1.00 (0.79&#x02013;1.26)</td><td align="center">1.00</td><td align="center">0.94 (0.74&#x02013;1.19)</td><td align="center">0.61</td></tr><tr><td align="left"><italic>FGFR4 </italic>rs376618</td><td align="center">0.88 (0.67&#x02013;1.14)</td><td align="center">0.33</td><td align="left">1.04 (0.83&#x02013;1.31)</td><td align="center">0.73</td><td align="center">0.87 (0.69&#x02013;1.11)</td><td align="center">0.27</td></tr><tr><td align="left"><italic>FGFR4 </italic>rs351855</td><td align="center">1.09 (0.87&#x02013;1.38)</td><td align="center">0.44</td><td align="left">0.90 (0.73&#x02013;1.12)</td><td align="center">0.35</td><td align="center">1.13 (0.93&#x02013;1.39)</td><td align="center">0.21</td></tr></tbody></table><table-wrap-foot><p>*Unconditional logistic regression adjusted for age.</p><p>**The SNP rs1966265 failed the assay and the rs12519145 was genotyped instead (r<sup>2 </sup>= 0.8).</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Haplotypes for the SNPs in the <italic>FGFR2 </italic>and <italic>FGFR4 </italic>genes and skin cancer risk</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center" colspan="4"><bold><italic>FGFR2</italic></bold></td><td></td><td></td><td align="center" colspan="2"><bold>Melanoma</bold></td><td align="center" colspan="2"><bold>SCC</bold></td><td align="center" colspan="2"><bold>BCC</bold></td></tr></thead><tbody><tr><td></td><td></td><td></td><td></td><td align="center" colspan="2">Controls</td><td align="center" colspan="2">Cases</td><td align="center" colspan="2">Cases</td><td align="center" colspan="2">Cases</td></tr><tr><td colspan="12"><hr></hr></td></tr><tr><td align="center">A</td><td align="center">B</td><td align="center">C</td><td align="center">D</td><td align="center">n</td><td align="center">%</td><td align="center">n</td><td align="center">%</td><td align="center">n</td><td align="center">%</td><td align="center">n</td><td align="center">%</td></tr><tr><td colspan="12"><hr></hr></td></tr><tr><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">779</td><td align="center">56.4</td><td align="center">166</td><td align="center">55.3</td><td align="center">286</td><td align="center">59.8</td><td align="center">270</td><td align="center">55.1</td></tr><tr><td></td><td></td><td></td><td></td><td align="center" colspan="2">Multivariate OR</td><td align="center" colspan="2">1.00</td><td align="center" colspan="2">1.00</td><td align="center" colspan="2">1.00</td></tr><tr><td align="center">1</td><td align="center">1</td><td align="center">1</td><td align="center">1</td><td align="center">532</td><td align="center">38.5</td><td align="center">118</td><td align="center">39.3</td><td align="center">177</td><td align="center">37.0</td><td align="center">196</td><td align="center">40.0</td></tr><tr><td></td><td></td><td></td><td></td><td align="center" colspan="2">Multivariate OR</td><td align="center" colspan="2">1.06 (0.82&#x02013;1.38)</td><td align="center" colspan="2">0.90 (0.72&#x02013;1.11)</td><td align="center" colspan="2">1.06 (0.85&#x02013;1.32)</td></tr><tr><td align="center">1</td><td align="center">1</td><td align="center">0</td><td align="center">0</td><td align="center">25</td><td align="center">1.8</td><td align="center">3</td><td align="center">1.0</td><td align="center">8</td><td align="center">1.7</td><td align="center">8</td><td align="center">1.6</td></tr><tr><td></td><td></td><td></td><td></td><td align="center" colspan="2">Multivariate OR</td><td align="center" colspan="2">0.55 (0.16&#x02013;1.89)</td><td align="center" colspan="2">0.89 (0.39&#x02013;2.00)</td><td align="center" colspan="2">0.90 (0.40&#x02013;2.05)</td></tr><tr><td align="center">1</td><td align="center">1</td><td align="center">1</td><td align="center">0</td><td align="center">17</td><td align="center">1.2</td><td align="center">8</td><td align="center">2.7</td><td align="center">3</td><td align="center">0.6</td><td align="center">6</td><td align="center">1.2</td></tr><tr><td></td><td></td><td></td><td></td><td align="center" colspan="2">Multivariate OR</td><td align="center" colspan="2">2.42 (1.00&#x02013;5.87)</td><td align="center" colspan="2">0.46 (0.13&#x02013;1.60)</td><td align="center" colspan="2">1.03 (0.40&#x02013;2.69)</td></tr><tr><td align="center" colspan="4">Rare &#x0003c; 1%</td><td align="center">29</td><td align="center">2.1</td><td align="center">5</td><td align="center">1.7</td><td align="center">4</td><td align="center">0.8</td><td align="center">10</td><td align="center">2.1</td></tr><tr><td></td><td></td><td></td><td></td><td align="center" colspan="2">Multivariate OR</td><td align="center" colspan="2">0.80 (0.31&#x02013;2.06)</td><td align="center" colspan="2">0.41 (0.15&#x02013;1.13)</td><td align="center" colspan="2">0.98 (0.50&#x02013;1.93)</td></tr><tr><td colspan="12"><hr></hr></td></tr><tr><td align="left" colspan="12">A: rs11200014; B: rs2981579; C: rs1219648; D: rs2420946</td></tr><tr><td colspan="12"><hr></hr></td></tr><tr><td/><td align="center" colspan="3"><bold><italic>FGFR4</italic></bold></td><td></td><td></td><td align="center" colspan="2"><bold>Melanoma</bold></td><td align="center" colspan="2"><bold>SCC</bold></td><td align="center" colspan="2"><bold>BCC</bold></td></tr><tr><td colspan="12"><hr></hr></td></tr><tr><td></td><td></td><td></td><td></td><td align="center" colspan="2">Controls</td><td align="center" colspan="2">Cases</td><td align="center" colspan="2">Cases</td><td align="center" colspan="2">Cases</td></tr><tr><td colspan="12"><hr></hr></td></tr><tr><td></td><td align="center">A</td><td align="center">B</td><td align="center">C</td><td align="center">n</td><td align="center">%</td><td align="center">n</td><td align="center">%</td><td align="center">n</td><td align="center">%</td><td align="center">n</td><td align="center">%</td></tr><tr><td colspan="12"><hr></hr></td></tr><tr><td></td><td align="center">0</td><td align="center">0</td><td align="center">1</td><td align="center">446</td><td align="center">29.7</td><td align="center">118</td><td align="center">30.7</td><td align="center">121</td><td align="center">25.8</td><td align="center">164</td><td align="center">32.2</td></tr><tr><td></td><td></td><td></td><td></td><td align="center" colspan="2">Multivariate OR</td><td align="center" colspan="2">1.00</td><td align="center" colspan="2">1.00</td><td align="center" colspan="2">1.00</td></tr><tr><td></td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">391</td><td align="center">26.0</td><td align="center">89</td><td align="center">23.2</td><td align="center">130</td><td align="center">27.7</td><td align="center">133</td><td align="center">26.1</td></tr><tr><td></td><td></td><td></td><td></td><td align="center" colspan="2">Multivariate OR</td><td align="center" colspan="2">0.86 (0.63&#x02013;1.17)</td><td align="center" colspan="2">1.22 (0.92&#x02013;1.62)</td><td align="center" colspan="2">0.93 (0.71&#x02013;1.21)</td></tr><tr><td></td><td align="center">0</td><td align="center">1</td><td align="center">0</td><td align="center">343</td><td align="center">22.8</td><td align="center">83</td><td align="center">21.7</td><td align="center">113</td><td align="center">24.0</td><td align="center">106</td><td align="center">20.9</td></tr><tr><td></td><td></td><td></td><td></td><td align="center" colspan="2">Multivariate OR</td><td align="center" colspan="2">0.91 (0.66&#x02013;1.26)</td><td align="center" colspan="2">1.21 (0.90&#x02013;1.64)</td><td align="center" colspan="2">0.82 (0.62&#x02013;1.10)</td></tr><tr><td></td><td align="center">1</td><td align="center">0</td><td align="center">0</td><td align="center">293</td><td align="center">19.5</td><td align="center">84</td><td align="center">22.0</td><td align="center">95</td><td align="center">20.3</td><td align="center">95</td><td align="center">18.8</td></tr><tr><td></td><td></td><td></td><td></td><td align="center" colspan="2">Multivariate OR</td><td align="center" colspan="2">1.08 (0.78&#x02013;1.49)</td><td align="center" colspan="2">1.19 (0.88&#x02013;1.62)</td><td align="center" colspan="2">0.88 (0.66&#x02013;1.18)</td></tr><tr><td></td><td align="center" colspan="3">Rare &#x0003c; 1%</td><td align="center">30</td><td align="center">2.0</td><td align="center">9</td><td align="center">2.4</td><td align="center">10</td><td align="center">2.2</td><td align="center">10</td><td align="center">1.9</td></tr><tr><td></td><td></td><td></td><td></td><td align="center" colspan="2">Multivariate OR</td><td align="center" colspan="2">1.21 (0.49&#x02013;2.96)</td><td align="center" colspan="2">1.31 (0.55&#x02013;3.10)</td><td align="center" colspan="2">0.89 (0.37&#x02013;2.16)</td></tr><tr><td colspan="12"><hr></hr></td></tr><tr><td align="left" colspan="12">A: rs1966265*; B: rs376618; C: rs351855</td></tr></tbody></table><table-wrap-foot><p>0, common allele; 1, rare allele.</p><p>Logistic regression adjusted for age.</p><p><italic>p</italic>-values for global tests are &#x0003e;0.05.</p><p>*The SNP rs1966265 failed the assay and the rs12519145 was genotyped instead (r<sup>2 </sup>= 0.8).</p></table-wrap-foot></table-wrap><p>The potential contribution of the FGF/FGFR family to the development of skin cancer has been suggested. For example, the basic FGF (bFGF) alternatively named <italic>FGF2 </italic>binds to distinct splice variants of the four FGFRs and acts as a potent activator in the proliferation and differentiation of melanocytes [<xref ref-type="bibr" rid="B45">45</xref>]. It has been noted that the combination of bFGF with ultraviolet (UV) light, the main risk factor for skin cancer, may lead to cutaneous melanoma induction [<xref ref-type="bibr" rid="B46">46</xref>]. In this study, we assessed the associations between the genetic variants in the <italic>FGFR2 </italic>and <italic>FGFR4 </italic>genes and the three types of skin cancer simultaneously with a modest sample size in each cancer type. Only one study has attempted to assess the relation of the <italic>FGFR4 </italic>Gly388Arg with the progression of melanoma in melanoma patients, and observed that the <italic>FGFR4 </italic>Arg388 allele was associated with tumor thickness and nodular malignant melanoma [<xref ref-type="bibr" rid="B26">26</xref>]. We did not observe a significant association of this allele with skin cancer risk. It seems that this SNP acts as a potential marker for the progression of skin cancer rather than susceptibility to skin cancer. Spinola et al. reported similar results for lung adenocarcinoma, i.e., that this allele revealed association with progression of cancer but a lack of association with the risk of cancer [<xref ref-type="bibr" rid="B33">33</xref>]. <italic>FGFR2 </italic>possesses the largest genomic structure among the FGFR family, with at least 22 exons and 21 introns and has been implicated in distinct types of cancer [<xref ref-type="bibr" rid="B47">47</xref>]. Also, recent <italic>in vitro </italic>and <italic>in vivo </italic>studies showed that loss-of-function <italic>FGFR2 </italic>mutations occur in a subset of melanomas [<xref ref-type="bibr" rid="B48">48</xref>]. It would be important to comprehensively examine the association of the common genetic variants in the entire <italic>FGFR2 </italic>gene region with skin cancer risk.</p></sec><sec><title>Conclusion</title><p>In conclusion, we did not detect any contribution of genetic variants in the <italic>FGFR2 </italic>or <italic>FGFR4 </italic>genes to inherited predisposition to skin cancer among Caucasian women.</p></sec><sec><title>List of Abbreviations</title><p><bold>FGFR</bold>: Fibroblast Growth Factor Receptor; <bold>BCC</bold>: Basal Cell Carcinoma; <bold>SCC</bold>: Squamous Cell Carcinoma; <bold>OR</bold>: Odds Ratio; <bold>CI</bold>: Confidence Interval; <bold>UV</bold>: Ultraviolet.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>All authors have contributed to designing the study and analyzing and interpreting the data, as well as to the writing of the manuscript. All authors have read and approved this manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/9/172/prepub"/></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional File 1</title><p><bold>Supplementary Table S1. Associations between the seven SNPs in the <italic>FGFR2 </italic>and <italic>FGFR4 </italic>genes and skin cancer risk</bold>. The data provided represent the results of the associations between seven SNPs in the FGFR2 and FGFR4 genes and skin cancer risk.</p></caption><media xlink:href="1471-2407-9-172-S1.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>We thank Dr. Hardeep Ranu and Ms. Pati Soule of the Dana-Farber/Harvard Cancer Center High-Throughput Polymorphism Detection Core for their laboratory assistance, and Ms. Carolyn Guo for her programming support. We are indebted to the participants in the Nurses' Health Study for their dedication and commitment. This work was supported by National Institutes of Health research grants CA122838 and CA132175.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Itoh</surname><given-names>N</given-names></name><name><surname>Ornitz</surname><given-names>DM</given-names></name></person-group><article-title>Evolution of the Fgf and Fgfr gene families</article-title><source>Trends Genet</source><year>2004</year><volume>20</volume><fpage>563</fpage><lpage>569</lpage><pub-id pub-id-type="pmid">15475116</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ornitz</surname><given-names>DM</given-names></name><name><surname>Itoh</surname><given-names>N</given-names></name></person-group><article-title>Fibroblast growth factors</article-title><source>Genome Biol</source><year>2001</year><volume>2</volume><fpage>REVIEWS3005</fpage><pub-id pub-id-type="pmid">11276432</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chellaiah</surname><given-names>AT</given-names></name><name><surname>McEwen</surname><given-names>DG</given-names></name><name><surname>Werner</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Ornitz</surname><given-names>DM</given-names></name></person-group><article-title>Fibroblast growth factor receptor (FGFR) 3. Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/FGF-1</article-title><source>J Biol Chem</source><year>1994</year><volume>269</volume><fpage>11620</fpage><lpage>11627</lpage><pub-id pub-id-type="pmid">7512569</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ornitz</surname><given-names>DM</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Colvin</surname><given-names>JS</given-names></name><name><surname>McEwen</surname><given-names>DG</given-names></name><name><surname>MacArthur</surname><given-names>CA</given-names></name><name><surname>Coulier</surname><given-names>F</given-names></name><name><surname>Gao</surname><given-names>G</given-names></name><name><surname>Goldfarb</surname><given-names>M</given-names></name></person-group><article-title>Receptor specificity of the fibroblast growth factor family</article-title><source>J Biol Chem</source><year>1996</year><volume>271</volume><fpage>15292</fpage><lpage>15297</lpage><pub-id pub-id-type="pmid">8663044</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orr-Urtreger</surname><given-names>A</given-names></name><name><surname>Bedford</surname><given-names>MT</given-names></name><name><surname>Burakova</surname><given-names>T</given-names></name><name><surname>Arman</surname><given-names>E</given-names></name><name><surname>Zimmer</surname><given-names>Y</given-names></name><name><surname>Yayon</surname><given-names>A</given-names></name><name><surname>Givol</surname><given-names>D</given-names></name><name><surname>Lonai</surname><given-names>P</given-names></name></person-group><article-title>Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2)</article-title><source>Dev Biol</source><year>1993</year><volume>158</volume><fpage>475</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">8393815</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>KG</given-names></name><name><surname>Werner</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Williams</surname><given-names>LT</given-names></name></person-group><article-title>Two FGF receptor genes are differentially expressed in epithelial and mesenchymal tissues during limb formation and organogenesis in the mouse</article-title><source>Development</source><year>1992</year><volume>114</volume><fpage>233</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">1315677</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stark</surname><given-names>KL</given-names></name><name><surname>McMahon</surname><given-names>JA</given-names></name><name><surname>McMahon</surname><given-names>AP</given-names></name></person-group><article-title>FGFR-4, a new member of the fibroblast growth factor receptor family, expressed in the definitive endoderm and skeletal muscle lineages of the mouse</article-title><source>Development</source><year>1991</year><volume>113</volume><fpage>641</fpage><lpage>651</lpage><pub-id pub-id-type="pmid">1723680</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>DE</given-names></name><name><surname>Williams</surname><given-names>LT</given-names></name></person-group><article-title>Structural and functional diversity in the FGF receptor multigene family</article-title><source>Adv Cancer Res</source><year>1993</year><volume>60</volume><fpage>1</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">8417497</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klint</surname><given-names>P</given-names></name><name><surname>Claesson-Welsh</surname><given-names>L</given-names></name></person-group><article-title>Signal transduction by fibroblast growth factor receptors</article-title><source>Front Biosci</source><year>1999</year><volume>4</volume><fpage>D165</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">9989949</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dmowski</surname><given-names>WP</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Rana</surname><given-names>N</given-names></name><name><surname>Fernandez</surname><given-names>BB</given-names></name><name><surname>Braun</surname><given-names>DP</given-names></name></person-group><article-title>Apoptosis in endometrial glandular and stromal cells in women with and without endometriosis</article-title><source>Hum Reprod</source><year>2001</year><volume>16</volume><fpage>1802</fpage><lpage>1808</lpage><pub-id pub-id-type="pmid">11527879</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eswarakumar</surname><given-names>VP</given-names></name><name><surname>Lax</surname><given-names>I</given-names></name><name><surname>Schlessinger</surname><given-names>J</given-names></name></person-group><article-title>Cellular signaling by fibroblast growth factor receptors</article-title><source>Cytokine Growth Factor Rev</source><year>2005</year><volume>16</volume><fpage>139</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">15863030</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taniguchi</surname><given-names>F</given-names></name><name><surname>Harada</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Yoshida</surname><given-names>S</given-names></name><name><surname>Iwabe</surname><given-names>T</given-names></name><name><surname>Tanikawa</surname><given-names>M</given-names></name><name><surname>Terakawa</surname><given-names>N</given-names></name></person-group><article-title>Keratinocyte growth factor in the promotion of human chorionic gonadotropin production in human choriocarcinoma cells</article-title><source>Am J Obstet Gynecol</source><year>2000</year><volume>182</volume><fpage>692</fpage><lpage>698</lpage><pub-id pub-id-type="pmid">10739532</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Danilenko</surname><given-names>DM</given-names></name><name><surname>Ring</surname><given-names>BD</given-names></name><name><surname>Yanagihara</surname><given-names>D</given-names></name><name><surname>Benson</surname><given-names>W</given-names></name><name><surname>Wiemann</surname><given-names>B</given-names></name><name><surname>Starnes</surname><given-names>CO</given-names></name><name><surname>Pierce</surname><given-names>GF</given-names></name></person-group><article-title>Keratinocyte growth factor is an important endogenous mediator of hair follicle growth, development, and differentiation. Normalization of the nu/nu follicular differentiation defect and amelioration of chemotherapy-induced alopecia</article-title><source>Am J Pathol</source><year>1995</year><volume>147</volume><fpage>145</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">7604876</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Werner</surname><given-names>S</given-names></name><name><surname>Weinberg</surname><given-names>W</given-names></name><name><surname>Liao</surname><given-names>X</given-names></name><name><surname>Peters</surname><given-names>KG</given-names></name><name><surname>Blessing</surname><given-names>M</given-names></name><name><surname>Yuspa</surname><given-names>SH</given-names></name><name><surname>Weiner</surname><given-names>RL</given-names></name><name><surname>Williams</surname><given-names>LT</given-names></name></person-group><article-title>Targeted expression of a dominant-negative FGF receptor mutant in the epidermis of transgenic mice reveals a role of FGF in keratinocyte organization and differentiation</article-title><source>EMBO J</source><year>1993</year><volume>12</volume><fpage>2635</fpage><lpage>2643</lpage><pub-id pub-id-type="pmid">7687538</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Werner</surname><given-names>S</given-names></name></person-group><article-title>Keratinocyte growth factor: a unique player in epithelial repair processes</article-title><source>Cytokine Growth Factor Rev</source><year>1998</year><volume>9</volume><fpage>153</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">9754709</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grose</surname><given-names>R</given-names></name><name><surname>Fantl</surname><given-names>V</given-names></name><name><surname>Werner</surname><given-names>S</given-names></name><name><surname>Chioni</surname><given-names>AM</given-names></name><name><surname>Jarosz</surname><given-names>M</given-names></name><name><surname>Rudling</surname><given-names>R</given-names></name><name><surname>Cross</surname><given-names>B</given-names></name><name><surname>Hart</surname><given-names>IR</given-names></name><name><surname>Dickson</surname><given-names>C</given-names></name></person-group><article-title>The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development</article-title><source>EMBO J</source><year>2007</year><volume>26</volume><fpage>1268</fpage><lpage>1278</lpage><pub-id pub-id-type="pmid">17304214</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>KB</given-names></name><name><surname>Maia</surname><given-names>AT</given-names></name><name><surname>O'Reilly</surname><given-names>M</given-names></name><name><surname>Teschendorff</surname><given-names>AE</given-names></name><name><surname>Chin</surname><given-names>SF</given-names></name><name><surname>Caldas</surname><given-names>C</given-names></name><name><surname>Ponder</surname><given-names>BA</given-names></name></person-group><article-title>Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer</article-title><source>PLoS Biol</source><year>2008</year><volume>6</volume><fpage>e108</fpage><pub-id pub-id-type="pmid">18462018</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>JH</given-names></name><name><surname>Shin</surname><given-names>KH</given-names></name><name><surname>Park</surname><given-names>JG</given-names></name></person-group><article-title>Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>3541</fpage><lpage>3543</lpage><pub-id pub-id-type="pmid">11325814</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>T</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Kurebayashi</surname><given-names>J</given-names></name><name><surname>Asa</surname><given-names>SL</given-names></name><name><surname>Ezzat</surname><given-names>S</given-names></name></person-group><article-title>Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><fpage>5461</fpage><lpage>5470</lpage><pub-id pub-id-type="pmid">17545628</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pollock</surname><given-names>PM</given-names></name><name><surname>Gartside</surname><given-names>MG</given-names></name><name><surname>Dejeza</surname><given-names>LC</given-names></name><name><surname>Powell</surname><given-names>MA</given-names></name><name><surname>Mallon</surname><given-names>MA</given-names></name><name><surname>Davies</surname><given-names>H</given-names></name><name><surname>Mohammadi</surname><given-names>M</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Trent</surname><given-names>JM</given-names></name><name><surname>Goodfellow</surname><given-names>PJ</given-names></name></person-group><article-title>Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes</article-title><source>Oncogene</source><year>2007</year><volume>26</volume><fpage>7158</fpage><lpage>7162</lpage><pub-id pub-id-type="pmid">17525745</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ricol</surname><given-names>D</given-names></name><name><surname>Cappellen</surname><given-names>D</given-names></name><name><surname>El Marjou</surname><given-names>A</given-names></name><name><surname>Gil-Diez-de-Medina</surname><given-names>S</given-names></name><name><surname>Girault</surname><given-names>JM</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Ferry</surname><given-names>G</given-names></name><name><surname>Tucker</surname><given-names>G</given-names></name><name><surname>Poupon</surname><given-names>MF</given-names></name><name><surname>Chopin</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer</article-title><source>Oncogene</source><year>1999</year><volume>18</volume><fpage>7234</fpage><lpage>7243</lpage><pub-id pub-id-type="pmid">10602477</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yasumoto</surname><given-names>H</given-names></name><name><surname>Matsubara</surname><given-names>A</given-names></name><name><surname>Mutaguchi</surname><given-names>K</given-names></name><name><surname>Usui</surname><given-names>T</given-names></name><name><surname>McKeehan</surname><given-names>WL</given-names></name></person-group><article-title>Restoration of fibroblast growth factor receptor2 suppresses growth and tumorigenicity of malignant human prostate carcinoma PC-3 cells</article-title><source>Prostate</source><year>2004</year><volume>61</volume><fpage>236</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">15368475</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Easton</surname><given-names>DF</given-names></name><name><surname>Pooley</surname><given-names>KA</given-names></name><name><surname>Dunning</surname><given-names>AM</given-names></name><name><surname>Pharoah</surname><given-names>PD</given-names></name><name><surname>Thompson</surname><given-names>D</given-names></name><name><surname>Ballinger</surname><given-names>DG</given-names></name><name><surname>Struewing</surname><given-names>JP</given-names></name><name><surname>Morrison</surname><given-names>J</given-names></name><name><surname>Field</surname><given-names>H</given-names></name><name><surname>Luben</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Genome-wide association study identifies novel breast cancer susceptibility loci</article-title><source>Nature</source><year>2007</year><volume>447</volume><fpage>1087</fpage><lpage>1093</lpage><pub-id pub-id-type="pmid">17529967</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>DJ</given-names></name><name><surname>Kraft</surname><given-names>P</given-names></name><name><surname>Jacobs</surname><given-names>KB</given-names></name><name><surname>Cox</surname><given-names>DG</given-names></name><name><surname>Yeager</surname><given-names>M</given-names></name><name><surname>Hankinson</surname><given-names>SE</given-names></name><name><surname>Wacholder</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Welch</surname><given-names>R</given-names></name><name><surname>Hutchinson</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><fpage>870</fpage><lpage>874</lpage><pub-id pub-id-type="pmid">17529973</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kostrzewa</surname><given-names>M</given-names></name><name><surname>Muller</surname><given-names>U</given-names></name></person-group><article-title>Genomic structure and complete sequence of the human FGFR4 gene</article-title><source>Mamm Genome</source><year>1998</year><volume>9</volume><fpage>131</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">9457674</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Streit</surname><given-names>S</given-names></name><name><surname>Mestel</surname><given-names>DS</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Ullrich</surname><given-names>A</given-names></name><name><surname>Berking</surname><given-names>C</given-names></name></person-group><article-title>FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients</article-title><source>Br J Cancer</source><year>2006</year><volume>94</volume><fpage>1879</fpage><lpage>1886</lpage><pub-id pub-id-type="pmid">16721364</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jaakkola</surname><given-names>S</given-names></name><name><surname>Salmikangas</surname><given-names>P</given-names></name><name><surname>Nylund</surname><given-names>S</given-names></name><name><surname>Partanen</surname><given-names>J</given-names></name><name><surname>Armstrong</surname><given-names>E</given-names></name><name><surname>Pyrhonen</surname><given-names>S</given-names></name><name><surname>Lehtovirta</surname><given-names>P</given-names></name><name><surname>Nevanlinna</surname><given-names>H</given-names></name></person-group><article-title>Amplification of fgfr4 gene in human breast and gynecological cancers</article-title><source>Int J Cancer</source><year>1993</year><volume>54</volume><fpage>378</fpage><lpage>382</lpage><pub-id pub-id-type="pmid">8099571</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>HY</given-names></name><name><surname>Gullick</surname><given-names>WJ</given-names></name><name><surname>Lemoine</surname><given-names>NR</given-names></name></person-group><article-title>Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer</article-title><source>Int J Cancer</source><year>1994</year><volume>59</volume><fpage>667</fpage><lpage>675</lpage><pub-id pub-id-type="pmid">7960240</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sahadevan</surname><given-names>K</given-names></name><name><surname>Darby</surname><given-names>S</given-names></name><name><surname>Leung</surname><given-names>HY</given-names></name><name><surname>Mathers</surname><given-names>ME</given-names></name><name><surname>Robson</surname><given-names>CN</given-names></name><name><surname>Gnanapragasam</surname><given-names>VJ</given-names></name></person-group><article-title>Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer</article-title><source>J Pathol</source><year>2007</year><volume>213</volume><fpage>82</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">17607666</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>A</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Kakizoe</surname><given-names>T</given-names></name><name><surname>Miyao</surname><given-names>N</given-names></name><name><surname>Sugimura</surname><given-names>T</given-names></name><name><surname>Terada</surname><given-names>M</given-names></name><name><surname>Tsukamoto</surname><given-names>T</given-names></name></person-group><article-title>Identification of receptor genes in renal cell carcinoma associated with angiogenesis by differential hybridization technique</article-title><source>Biochem Biophys Res Commun</source><year>1999</year><volume>257</volume><fpage>855</fpage><lpage>859</lpage><pub-id pub-id-type="pmid">10208873</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bange</surname><given-names>J</given-names></name><name><surname>Prechtl</surname><given-names>D</given-names></name><name><surname>Cheburkin</surname><given-names>Y</given-names></name><name><surname>Specht</surname><given-names>K</given-names></name><name><surname>Harbeck</surname><given-names>N</given-names></name><name><surname>Schmitt</surname><given-names>M</given-names></name><name><surname>Knyazeva</surname><given-names>T</given-names></name><name><surname>Muller</surname><given-names>S</given-names></name><name><surname>Gartner</surname><given-names>S</given-names></name><name><surname>Sures</surname><given-names>I</given-names></name><etal></etal></person-group><article-title>Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><fpage>840</fpage><lpage>847</lpage><pub-id pub-id-type="pmid">11830541</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matakidou</surname><given-names>A</given-names></name><name><surname>El Galta</surname><given-names>R</given-names></name><name><surname>Rudd</surname><given-names>MF</given-names></name><name><surname>Webb</surname><given-names>EL</given-names></name><name><surname>Bridle</surname><given-names>H</given-names></name><name><surname>Eisen</surname><given-names>T</given-names></name><name><surname>Houlston</surname><given-names>RS</given-names></name></person-group><article-title>Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis</article-title><source>Br J Cancer</source><year>2007</year><volume>96</volume><fpage>1904</fpage><lpage>1907</lpage><pub-id pub-id-type="pmid">17519899</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spinola</surname><given-names>M</given-names></name><name><surname>Leoni</surname><given-names>V</given-names></name><name><surname>Pignatiello</surname><given-names>C</given-names></name><name><surname>Conti</surname><given-names>B</given-names></name><name><surname>Ravagnani</surname><given-names>F</given-names></name><name><surname>Pastorino</surname><given-names>U</given-names></name><name><surname>Dragani</surname><given-names>TA</given-names></name></person-group><article-title>Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>7307</fpage><lpage>7311</lpage><pub-id pub-id-type="pmid">16061909</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Streit</surname><given-names>S</given-names></name><name><surname>Bange</surname><given-names>J</given-names></name><name><surname>Fichtner</surname><given-names>A</given-names></name><name><surname>Ihrler</surname><given-names>S</given-names></name><name><surname>Issing</surname><given-names>W</given-names></name><name><surname>Ullrich</surname><given-names>A</given-names></name></person-group><article-title>Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma</article-title><source>Int J Cancer</source><year>2004</year><volume>111</volume><fpage>213</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">15197773</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thussbas</surname><given-names>C</given-names></name><name><surname>Nahrig</surname><given-names>J</given-names></name><name><surname>Streit</surname><given-names>S</given-names></name><name><surname>Bange</surname><given-names>J</given-names></name><name><surname>Kriner</surname><given-names>M</given-names></name><name><surname>Kates</surname><given-names>R</given-names></name><name><surname>Ulm</surname><given-names>K</given-names></name><name><surname>Kiechle</surname><given-names>M</given-names></name><name><surname>Hoefler</surname><given-names>H</given-names></name><name><surname>Ullrich</surname><given-names>A</given-names></name><name><surname>Harbeck</surname><given-names>N</given-names></name></person-group><article-title>FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>3747</fpage><lpage>3755</lpage><pub-id pub-id-type="pmid">16822847</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Stockton</surname><given-names>DW</given-names></name><name><surname>Ittmann</surname><given-names>M</given-names></name></person-group><article-title>The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><fpage>6169</fpage><lpage>6178</lpage><pub-id pub-id-type="pmid">15448004</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miettinen</surname><given-names>OS</given-names></name></person-group><article-title>Stratification by a multivariate confounder score</article-title><source>Am J Epidemiol</source><year>1976</year><volume>104</volume><fpage>609</fpage><lpage>620</lpage><pub-id pub-id-type="pmid">998608</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Colditz</surname><given-names>GA</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name></person-group><article-title>Risk factors for skin cancers: a nested case-control study within the Nurses' Health Study</article-title><source>Int J Epidemiol</source><year>2006</year><volume>35</volume><fpage>1514</fpage><lpage>1521</lpage><pub-id pub-id-type="pmid">16943234</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dausset</surname><given-names>J</given-names></name><name><surname>Cann</surname><given-names>H</given-names></name><name><surname>Cohen</surname><given-names>D</given-names></name><name><surname>Lathrop</surname><given-names>M</given-names></name><name><surname>Lalouel</surname><given-names>JM</given-names></name><name><surname>White</surname><given-names>R</given-names></name></person-group><article-title>Centre d'etude du polymorphisme humain (CEPH): collaborative genetic mapping of the human genome</article-title><source>Genomics</source><year>1990</year><volume>6</volume><fpage>575</fpage><lpage>577</lpage><pub-id pub-id-type="pmid">2184120</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carlson</surname><given-names>CS</given-names></name><name><surname>Eberle</surname><given-names>MA</given-names></name><name><surname>Rieder</surname><given-names>MJ</given-names></name><name><surname>Yi</surname><given-names>Q</given-names></name><name><surname>Kruglyak</surname><given-names>L</given-names></name><name><surname>Nickerson</surname><given-names>DA</given-names></name></person-group><article-title>Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium</article-title><source>Am J Hum Genet</source><year>2004</year><volume>74</volume><fpage>106</fpage><lpage>120</lpage><comment>Epub 2003 Dec 2015</comment><pub-id pub-id-type="pmid">14681826</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stram</surname><given-names>DO</given-names></name><name><surname>Leigh Pearce</surname><given-names>C</given-names></name><name><surname>Bretsky</surname><given-names>P</given-names></name><name><surname>Freedman</surname><given-names>M</given-names></name><name><surname>Hirschhorn</surname><given-names>JN</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Kolonel</surname><given-names>LN</given-names></name><name><surname>Henderson</surname><given-names>BE</given-names></name><name><surname>Thomas</surname><given-names>DC</given-names></name></person-group><article-title>Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals</article-title><source>Hum Hered</source><year>2003</year><volume>55</volume><fpage>179</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">14566096</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kraft</surname><given-names>P</given-names></name><name><surname>Cox</surname><given-names>DG</given-names></name><name><surname>Paynter</surname><given-names>RA</given-names></name><name><surname>Hunter</surname><given-names>D</given-names></name><name><surname>De Vivo</surname><given-names>I</given-names></name></person-group><article-title>Accounting for haplotype uncertainty in matched association studies: a comparison of simple and flexible techniques</article-title><source>Genet Epidemiol</source><year>2005</year><volume>28</volume><fpage>261</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">15637718</pub-id></citation></ref><ref id="B43"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Gauderman</surname><given-names>WJ</given-names></name><name><surname>Morrison</surname><given-names>JM</given-names></name></person-group><article-title>QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies</article-title><year>2006</year><ext-link ext-link-type="uri" xlink:href="http://hydra.usc.edu/gxe"/></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Colditz</surname><given-names>GA</given-names></name><name><surname>Liu</surname><given-names>JS</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name></person-group><article-title>Genetic variation in XPD, sun exposure, and risk of skin cancer</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2005</year><volume>14</volume><fpage>1539</fpage><lpage>1544</lpage><pub-id pub-id-type="pmid">15941969</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bikfalvi</surname><given-names>A</given-names></name><name><surname>Klein</surname><given-names>S</given-names></name><name><surname>Pintucci</surname><given-names>G</given-names></name><name><surname>Rifkin</surname><given-names>DB</given-names></name></person-group><article-title>Biological roles of fibroblast growth factor-2</article-title><source>Endocr Rev</source><year>1997</year><volume>18</volume><fpage>26</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">9034785</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berking</surname><given-names>C</given-names></name><name><surname>Takemoto</surname><given-names>R</given-names></name><name><surname>Satyamoorthy</surname><given-names>K</given-names></name><name><surname>Elenitsas</surname><given-names>R</given-names></name><name><surname>Herlyn</surname><given-names>M</given-names></name></person-group><article-title>Basic fibroblast growth factor and ultraviolet B transform melanocytes in human skin</article-title><source>Am J Pathol</source><year>2001</year><volume>158</volume><fpage>943</fpage><lpage>953</lpage><pub-id pub-id-type="pmid">11238042</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ingersoll</surname><given-names>RG</given-names></name><name><surname>Paznekas</surname><given-names>WA</given-names></name><name><surname>Tran</surname><given-names>AK</given-names></name><name><surname>Scott</surname><given-names>AF</given-names></name><name><surname>Jiang</surname><given-names>G</given-names></name><name><surname>Jabs</surname><given-names>EW</given-names></name></person-group><article-title>Fibroblast growth factor receptor 2 (FGFR2): genomic sequence and variations</article-title><source>Cytogenet Cell Genet</source><year>2001</year><volume>94</volume><fpage>121</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">11856867</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gartside</surname><given-names>MG</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Ibrahimi</surname><given-names>OA</given-names></name><name><surname>Byron</surname><given-names>SA</given-names></name><name><surname>Curtis</surname><given-names>AV</given-names></name><name><surname>Wellens</surname><given-names>CL</given-names></name><name><surname>Bengston</surname><given-names>A</given-names></name><name><surname>Yudt</surname><given-names>LM</given-names></name><name><surname>Eliseenkova</surname><given-names>AV</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma</article-title><source>Mol Cancer Res</source><year>2009</year><volume>7</volume><fpage>41</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">19147536</pub-id></citation></ref></ref-list></back></article> 